181 related articles for article (PubMed ID: 23459486)
1. Mechanism of action of efinaconazole, a novel triazole antifungal agent.
Tatsumi Y; Nagashima M; Shibanushi T; Iwata A; Kangawa Y; Inui F; Siu WJ; Pillai R; Nishiyama Y
Antimicrob Agents Chemother; 2013 May; 57(5):2405-9. PubMed ID: 23459486
[TBL] [Abstract][Full Text] [Related]
2. Biochemical changes associated with the antifungal action of the triazole ICI 153,066 on Candida albicans and Trichophyton quinckeanum.
Barrett-Bee K; Newboult L; Pinder P
FEMS Microbiol Lett; 1991 Apr; 63(2-3):127-31. PubMed ID: 2060756
[TBL] [Abstract][Full Text] [Related]
3. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.
Sanati H; Belanger P; Fratti R; Ghannoum M
Antimicrob Agents Chemother; 1997 Nov; 41(11):2492-6. PubMed ID: 9371355
[TBL] [Abstract][Full Text] [Related]
4. Biochemical mode of action and enantiomeric selectivity of SDZ 89-485, a new triazole antimycotic.
Ryder NS
J Med Vet Mycol; 1990; 28(5):385-94. PubMed ID: 2283585
[TBL] [Abstract][Full Text] [Related]
5. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.
Vanden Bossche H; Ausma J; Bohets H; Vermuyten K; Willemsens G; Marichal P; Meerpoel L; Odds F; Borgers M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3272-8. PubMed ID: 15328084
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of drug susceptibility test for Efinaconazole compared with conventional antifungal agents.
Hur MS; Park M; Jung WH; Lee YW
Mycoses; 2019 Mar; 62(3):291-297. PubMed ID: 30427072
[TBL] [Abstract][Full Text] [Related]
7. Dodonaea viscosa var angustifolia derived 5,6,8-trihydroxy-7,4' dimethoxy flavone inhibits ergosterol synthesis and the production of hyphae and biofilm in Candida albicans.
Patel M; Srivastava V; Ahmad A
J Ethnopharmacol; 2020 Sep; 259():112965. PubMed ID: 32413575
[TBL] [Abstract][Full Text] [Related]
8. Efinaconazole (Jublia) for the treatment of onychomycosis.
Gupta AK; Simpson FC
Expert Rev Anti Infect Ther; 2014 Jul; 12(7):743-52. PubMed ID: 24850511
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of a new mycotic agent, piritetrate on ergosterol biosynthesis in pathogenic fungi.
Morita T; Iwata K; Nozawa Y
J Med Vet Mycol; 1989; 27(1):17-25. PubMed ID: 2666631
[TBL] [Abstract][Full Text] [Related]
10. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis.
Heimark L; Shipkova P; Greene J; Munayyer H; Yarosh-Tomaine T; DiDomenico B; Hare R; Pramanik BN
J Mass Spectrom; 2002 Mar; 37(3):265-9. PubMed ID: 11921367
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ergosterol synthesis in Candida albicans by novel eugenol tosylate congeners targeting sterol 14α-demethylase (CYP51) enzyme.
Lone SA; Khan S; Ahmad A
Arch Microbiol; 2020 May; 202(4):711-726. PubMed ID: 31786635
[TBL] [Abstract][Full Text] [Related]
13. Effects of antifungal agents on ergosterol biosynthesis in Candida albicans and Trichophyton mentagrophytes: differential inhibitory sites of naphthiomate and miconazole.
Morita T; Nozawa Y
J Invest Dermatol; 1985 Nov; 85(5):434-7. PubMed ID: 3902987
[TBL] [Abstract][Full Text] [Related]
14. The mode of antifungal action of tolnaftate.
Barrett-Bee KJ; Lane AC; Turner RW
J Med Vet Mycol; 1986 Apr; 24(2):155-60. PubMed ID: 3522841
[TBL] [Abstract][Full Text] [Related]
15. Novel high energy intermediate analogues with triazasterol-related structures as inhibitors of ergosterol biosynthesis. III. Synthesis and antifungal activity of N4-alkyl-1,6,7,11b-tetrahydro-2H-pyrimido[4,3-a]isoquinolin-4-amine salts.
Gössnitzer E; Punkenhofer A; Amon A; Favre B
Eur J Pharm Sci; 2003 Jun; 19(2-3):151-64. PubMed ID: 12791418
[TBL] [Abstract][Full Text] [Related]
16. Antifungal activity of xanthones: evaluation of their effect on ergosterol biosynthesis by high-performance liquid chromatography.
Pinto E; Afonso C; Duarte S; Vale-Silva L; Costa E; Sousa E; Pinto M
Chem Biol Drug Des; 2011 Mar; 77(3):212-22. PubMed ID: 21244637
[TBL] [Abstract][Full Text] [Related]
17. β-lactam substituted polycyclic fused pyrrolidine/pyrrolizidine derivatives eradicate C. albicans in an ex vivo human dentinal tubule model by inhibiting sterol 14-α demethylase and cAMP pathway.
Gowri M; Sofi Beaula W; Biswal J; Dhamodharan P; Saiharish R; Rohan prasad S; Pitani R; Kandaswamy D; Raghunathan R; Jeyakanthan J; Rayala SK; Venkatraman G
Biochim Biophys Acta; 2016 Apr; 1860(4):636-47. PubMed ID: 26723175
[TBL] [Abstract][Full Text] [Related]
18. Saperconazole: a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes.
Vanden Bossche H; Marichal P; Willemsens G; Bellens D; Gorrens J; Roels I; Coene MC; Le Jeune L; Janssen PA
Mycoses; 1990; 33(7-8):335-52. PubMed ID: 2090934
[TBL] [Abstract][Full Text] [Related]
19. The effects of saperconazole on the morphology of Candida albicans, Pityrosporum ovale and Trichophyton rubrum in vitro.
Jansen T; Borgers M; van de Ven MA; Xhonneux B; Wouters L; van Gerven F; van Cutsem J
J Med Vet Mycol; 1991; 29(5):293-303. PubMed ID: 1955949
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal.
Iwata A; Watanabe Y; Kumagai N; Katafuchi-Nagashima M; Sugiura K; Pillai R; Tatsumi Y
Antimicrob Agents Chemother; 2014 Aug; 58(8):4920-2. PubMed ID: 24867968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
